Fostemsavir - ViiV Healthcare

Drug Profile

Fostemsavir - ViiV Healthcare

Alternative Names: BMS 626529 prodrug; BMS-663068; BMS-663068-03; Fostemsavir tromethamine; GSK 3684934; GSK-3684934A; HIV attachment inhibitor - ViiV Healthcare; Temsavir prodrug

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; ViiV Healthcare
  • Class 2 ring heterocyclic compounds; Antiretrovirals; Phosphoric acid esters; Piperazines; Pyridines; Pyrroles; Small molecules; Triazoles
  • Mechanism of Action Virus attachment inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 27 Oct 2017 ViiV Healthcare plans regulatory submissions in the 2019-2020 timeframe
  • 27 Oct 2017 Adverse events and efficacy data from the phase III BRIGHTE trial in HIV-1 infections (Treatment-experienced) released by ViiV Healthcare
  • 04 Oct 2017 Pharmacokinetic and adverse events data from a phase I trial in Hepatic impairment presented at the IDWeek 2017 (IDW-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top